VYNE Therapeutics Reports Disappointing Phase 2b Results for Repibresib Gel in Vitiligo Trial, Shares Drop 73% VYNE Therapeutics Inc. (Nasdaq: VYNE) announced topline results from its Phase 2b trial evaluating Repibresib gel for the treatment of nonsegmental vitiligo, a

Nasdaq: #VYNE
#VYNETherapeutics shares plunge as Repibresib gel misses primary endpoints in Phase 2b vitiligo trial. Despite some signs of efficacy at the highest dose, VYNE is discontinuing the study and seeking a partner for further development.

prismmarketview.com/vyne-therape...